Sanofi-Aventis Zimulti (clarification)
FDA data analysis presented at a recent advisory committee on rimonabant for weight loss suggests the product has a greater suicidality risk than competitors; it did not specifically address class risk for suicidality (1"The Pink Sheet" June 25, 2007, p. 23). Some of the data presented at the advisory committee session also was drawn from animal studies...
You may also be interested in...
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.
Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.